Discover how Poland’s Medical Research Agency (ABM) has reshaped the clinical trials landscape in just five years, gaining global recognition for advancing oncology, rare disease research, and pediatric studies.
Poland is making waves in the global medical research community, thanks to the transformative efforts of the Medical Research Agency (ABM). Since its establishment in 2019, the ABM has spearheaded significant advancements in clinical trials, positioning Poland as a key player in the international healthcare innovation ecosystem.
A recently published article in The Lancet Regional Health – Europe, titled “Medical Research Agency: 5 years of reshaping the clinical trials ecosystem in Poland”, outlines the agency’s remarkable achievements. Over the past five years, ABM has signed 315 research funding agreements worth over PLN 4.3 billion, granting more than 51,000 patients—13,000 of whom have rare conditions—access to groundbreaking therapies. This includes major developments in oncology, cardiology, neurology, and rare diseases, areas often neglected by global funding systems.
Transforming the Clinical Trials Landscape
The ABM has introduced innovative initiatives to modernize clinical research in Poland. Clinical Trials Support Centers (CTSCs) and Regional Digital Medicine Centers (RDMCs) have elevated Poland to the forefront of European medical innovation. These initiatives improve patient access to cutting-edge therapies and enhance the country’s research infrastructure, solidifying its reputation as a leader in digital and precision medicine.
Championing Pediatric and Rare Disease Research
The World Health Organization (WHO) has long called for increased pediatric representation in clinical research, and Poland is answering that call. ABM’s targeted funding ensures that often-overlooked areas, such as pediatric and rare disease research, receive the attention they deserve. This approach not only addresses unmet clinical needs but also advances global understanding of these challenging conditions.
Educating Future Scientists
In addition to its funding and infrastructure efforts, ABM is nurturing the next generation of scientific talent. Collaborative programs with institutions like Harvard Medical School are preparing Polish researchers to design and publish world-class studies, ensuring that Poland remains at the forefront of medical discovery.
A Growing Global Presence
Recognition in The Lancet—one of the world’s most prestigious medical journals—highlights Poland’s growing role in international biomedical research. ABM’s initiatives have enabled Polish scientists to join global research collaborations, reinforcing the country’s position as a key partner in medical innovation.
With a commitment to equitable funding models, cutting-edge infrastructure, and strategic education programs, Poland is proving that it is not only meeting but exceeding the global standards for clinical research. As the ABM continues to drive progress, the nation is poised to remain a vital force in shaping the future of healthcare worldwide.